The estimated Net Worth of Barbara Kahn is at least $11.3 Million dollars as of 10 February 2022. Barbara Kahn owns over 4,666 units of Dexcom Inc stock worth over $205,410 and over the last 14 years he sold DXCM stock worth over $10,738,120. In addition, he makes $316,954 as Independent Director at Dexcom Inc.
Sign up
Barbara Kahn DXCM stock SEC Form 4 insiders trading
Barbara has made over 14 trades of the Dexcom Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 4,666 units of DXCM stock worth $2,064,005 on 10 February 2022.
The largest trade he's ever made was selling 12,500 units of Dexcom Inc stock on 8 May 2014 worth over $690,375. On average, Barbara trades about 2,661 units every 107 days since 2011. As of 10 February 2022 he still owns at least 3,000 units of Dexcom Inc stock.
You can see the complete history of Barbara Kahn stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Barbara Kahn biography
Dr. Barbara E. Kahn serves as Independent Director of the Company. She has served on our Board since April 2011. Since January 2011, Dr. Kahn has served as the Patty and Jay H. Baker Professor of Marketing at The Wharton School, where she previously served as the Director of the Jay H. Baker Retailing Center from January 2011 to June 2017, Vice Dean of Wharton Undergraduate Division from 2003 to 2007, and the Dorothy Silberberg Professor of Marketing from June 1990 to July 2007. Dr. Kahn is currently serving as Executive Director of Marketing Science Institute (MSI). Prior to rejoining Wharton, Dr. Kahn served for three and a half years as the Dean and Schein Family Chair Professor of Marketing at the School of Business Administration, University of Miami, Coral Gables, Florida from August 2007 to January 2011. Dr. Kahn received her Ph.D., M.B.A. and M.Phil degrees from Columbia University, and a B.A. in English Literature from the University of Rochester.
What is the salary of Barbara Kahn?
As the Independent Director of Dexcom Inc, the total compensation of Barbara Kahn at Dexcom Inc is $316,954. There are 14 executives at Dexcom Inc getting paid more, with Kevin Sayer having the highest compensation of $10,279,400.
How old is Barbara Kahn?
Barbara Kahn is 67, he's been the Independent Director of Dexcom Inc since 2011. There are 3 older and 26 younger executives at Dexcom Inc. The oldest executive at Dexcom Inc is Andrew K. Balo, 73, who is the Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel..
What's Barbara Kahn's mailing address?
Barbara's mailing address filed with the SEC is 6340, Sequence Drive, Sorrento Valley, San Diego, San Diego County, California, 92121, United States.
Insiders trading at Dexcom Inc
Over the last 20 years, insiders at Dexcom Inc have traded over $724,717,982 worth of Dexcom Inc stock and bought 165,450 units worth $3,489,100 . The most active insiders traders include Sean Carney, Kim D Blickenstaff, and Steven R Altman. On average, Dexcom Inc executives and independent directors trade stock every 7 days with the average trade being worth of $892,438. The most recent stock trade was executed by Sadie Stern on 9 September 2024, trading 426 units of DXCM stock currently worth $29,458.
What does Dexcom Inc do?
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.
What does Dexcom Inc's logo look like?
Complete history of Barbara Kahn stock trades at Dexcom Inc
Dexcom Inc executives and stock owners
Dexcom Inc executives and other stock owners filed with the SEC include:
-
Kevin Sayer,
Chairman of the Board, President, Chief Executive Officer -
Quentin Blackford,
Chief Financial Officer, Chief Operating Officer -
Richard Doubleday,
Executive Vice President, Chief Commercial Officer -
Andrew Balo,
Executive Vice President - Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development -
Steven Pacelli,
Executive Vice President - Strategy and Corporate Development -
Donald Abbey,
Executive Vice President - Quality and Regulatory Affairs -
Kevin Ronald Sayer,
Exec. Chairman, CEO & Pres -
Jacob Steven Leach,
Exec. VP & CTO -
Bridgette Heller,
Independent Director -
Mark Foletta,
Lead Independent Director -
Eric Topol,
Independent Director -
Jay Skyler,
Independent Director -
Nicholas Augustinos,
Independent Director -
Steven Altman,
Independent Director -
Barbara Kahn,
Independent Director -
Richard Collins,
Independent Director -
Kyle Malady,
Independent Director -
Karen Dahut,
Independent Director -
Shelly Selvaraj,
Senior Vice President - Information Technology -
Jeffrey Moy,
Senior Vice President - Operations -
Jereme Sylvain,
Senior Vice President - Finance, Chief Accounting Officer -
Patrick Murphy,
Executive Vice President, Chief Legal Officer -
Jake Leach,
Executive Vice President, Chief Technology Officer -
Shelly Ramasamy Selvaraj,
Sr. VP of Information Technology -
Donald M. Abbey,
Exec. VP of Global Bus. Services, IT, Quality & Regulatory Affairs -
Steven R. Pacelli,
Exec. VP & MD of Dexcom Ventures -
Andrew K. Balo,
Exec. VP of Regulatory Strategy, Clinical Affairs & Strategic Partnership Devel. -
Sadie M. Stern,
Exec. VP & Chief HR Officer -
Chad M. Patterson,
Exec. VP of Global Marketing -
Sean Christensen,
Director of Corp. Affairs & Head of Investor Relations -
Jereme M. Sylvain,
Exec. VP, CFO & Chief Accounting Officer -
John Lister,
VP, Legal Affairs -
Terrance H Gregg,
Director -
Jess Roper,
VP, CFO -
Jorge A Valdes,
Vice President of Engineering -
Girish Naganathan,
EVP Chief Technology Officer -
Heather S Ace,
SVP Human Resources -
Kevin M Sun,
VP, Corp Controller & Treasury -
Jonathan T Md Lord,
Director -
Glen D Nelson,
Director -
Peter Gerhardsson,
VP, Int'l Business Development -
David Carner,
VP, Quality Assurance -
Laura Johnson,
V.P., Intellectual Property -
Martin Doordan,
Director -
Sean Carney,
Director -
John Riolo,
VP of Quality Assurance -
Claudia Graham,
VP, Marketing -
Donald A Lucas,
Director -
Donald L Lucas,
Director -
Mark Brister,
VP, Advanced Development Teams -
Richard Yang,
V.P., Strategic Affairs -
James H Brauker,
VP, Research & Development -
Rodney L Kellogg,
Vice President of Sales -
Andrew P Rasdal,
President and CEO -
Steven J Kemper,
Chief Financial Officer -
Kim D Blickenstaff,
Director -
Tae Andrews,
Vice President of Marketing -
Paul Travelers Companies In...,
-
Pincus Private Equity Viii ...,
-
Brenton Karl Ahrens,
Director -
Nancy Sfog City Management ...,
-
Equity Partners Ii Llccanaa...,
-
Paul Travelers Companies In...,
-
Eric A Charmers Landing Llc...,
-
Scott Lwindamere Llcwindame...,
-
Equity Partners Ii Llc Waub...,
-
Teri L Lawver,
EVP Chief Commercial Officer -
Paul R Flynn,
EVP Global Revenue -
Matthew Vincent Dolan,
EVP Strategy and Corporate Dev -
Sumi Shrishrimal,
SVP Chief Risk Officer -
Chad Patterson,
EVP Global Marketing -
Barry J. Regan,
EVP Operations -
Jacob Steven Leach,
EVP, Chief Operating Officer -
Rimma Driscoll,
Director -
Michael Jon Brown,
EVP, Chief Legal Officer -
Sadie Stern,
EVP, Chief HR Officer